MEDIPAL and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for MPS IIIB MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Co., Ltd. (TSE: 4552) announced that the first participant has been dosed in the global Phase I/II…
BioLab Holdings Expands Placental Membrane Portfolio With New Membrane Wrap Amniotic Hydro BioLab Holdings, Inc., a Phoenix-based medical technology company focused on tissue restoration, has expanded its portfolio of placental membrane products with the addition of Membrane Wrap™ Amniotic Hydro.…
PureTech Health Notes Positive Phase 1 Driving Trial Results for GlyphAllo in Major Depressive Disorder PureTech Health plc (LSE: PRTC), a biotherapeutics company operating through a hub-and-spoke model to translate scientific innovation into potentially transformative medicines, has highlighted positive topline…
TRIANA Biomedicines Publishes Nature Study Supporting TRI-611 Molecular Glue Therapy for ALK-Positive NSCLC TRIANA Biomedicines, Inc. (TRIANA), a clinical-stage biopharmaceutical company focused on developing molecular glue therapies against difficult-to-drug disease targets, has announced the publication of new preclinical research supporting…
PhenoNet Completes Enrollment in Phase IIb Trial of PHENOGENE-1A for ALS PhenoNet, Inc., a clinical-stage biotechnology company developing investigational therapies for neurodegenerative diseases, has announced the completion of recruitment and randomization in its Phase IIb clinical trial evaluating PHENOGENE-1A as…
Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-663 for Multiple Cancers Crossbow Therapeutics, Inc., a biotechnology company developing targeted antibody therapies designed to address a broad range of cancers, has announced the dosing of the first participant…
Gilead Sciences Opens New Research Center in Foster City to Accelerate Biomedical Innovation Gilead Sciences, Inc. (Nasdaq: GILD) has officially opened a new 182,000-square-foot Research Center at its headquarters in Foster City, California, marking a significant expansion of the company’s…
Endeavor BioMedicines Reports Positive Quantitative Imaging Results for Taladegib in Idiopathic Pulmonary Fibrosis Endeavor BioMedicines, a clinical-stage biotechnology company focused on developing medicines with the potential to deliver transformational benefits to patients with life-threatening diseases, has announced new quantitative imaging…
Coya Therapeutics Publishes Preclinical Findings for COYA 303 in Neuroinflammation Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company focused on developing biologic therapies designed to enhance regulatory T-cell (Treg) function, has announced the publication of new preclinical findings evaluating…
Compass Pathways to Highlight Treatment-Resistant Depression Research and Launch New HCP Education Campaign at Psych Congress 2026 Compass Pathways plc (Nasdaq: CMPS), a biotechnology company focused on developing new treatment options for mental health conditions, has announced its participation in…
Alzheon Reports Biomarker Findings Supporting Potential Disease-Modifying Effects of Valiltramiprosate in Early Alzheimer’s Disease Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing investigational therapies and diagnostic assays for Alzheimer’s disease (AD) and other neurodegenerative disorders, has announced the peer-reviewed…
Agilent Launches S540MD Slide Scanner in the U.S. Following FDA Clearance Agilent Technologies Inc. has announced the U.S. launch of the Agilent S540MD Slide Scanner System, a whole slide imaging (WSI) digital scanner designed to support high-throughput digital pathology workflows.…